Atlas Trials

Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC

Clinical trial NCT05062837 · UNKNOWN

Trial details

NCT number
NCT05062837
Sponsor
Guangxi Medical University
Status
UNKNOWN
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
Hepatocellular Carcinoma
Start date
2021-06-01
Primary completion
2024-09-30
Enrollment
62

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.